AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02715856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care
Study NCT02715856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Follow-Up Care
Description: Undergo standard follow-up care
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02715856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03958097 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NK cell and PD-1 antibody
Description: Each patient enrolled the study will received both NK cell and PD-1 antibody.
Study NCT02206438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of C-LMA
Description: After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
Study NCT02206438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of air-Q according
Description: After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
Study NCT01682603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A (BOTOX 300U)
Study NCT02505672 — intervention group
Intervention type: RADIATION
Intervention: Chemoradiotherapy for nasopharyngeal carcinoma
Description: Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
Study NCT04843839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% Oph Susp
Description: Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
Study NCT04843839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Tears 0.5% Lubricant Eye Drops
Description: Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
Study NCT04125719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO
Study NCT04125719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab infusion
Study NCT03351959 — intervention group
Intervention type: RADIATION
Intervention: neo-adjuvant treatment
Description: long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
Study NCT02242903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3079514
Description: Administered SC
Study NCT02242903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3079514
Description: Administered IV
Study NCT02242903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02242903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT05084885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online therapy
Description: Standard counseling provided over the internet.
Study NCT04691596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App use instructions
Description: Received a basic training with the StepUp app
Study NCT04691596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App use instructions
Description: Received a basic training with the StepUp app
Study NCT06002594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group low-volume irrigation
Description: Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 4 ml of 0.9% sodium chloride(NaCl) solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
Study NCT06002594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group high-volume irrigation
Description: Before the procedure, infants' physiological parameters were measured using the Nellcor Bedside SpO2 Patient Monitoring System. The procedure duration and crying duration were recorded using the stopwatch on a Samsung Galaxy A50 phone. Nasal irrigation was performed using 20 ml of 0.9% NaCl solution. Physiological parameters were measured immediately after the procedure and five minutes later. Subsequently, breastfeeding was initiated for the baby. Physiological parameters during breastfeeding were measured, and parental satisfaction levels were evaluated. Then, the frequency of procedure repetitions was recorded.
Study NCT02124421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive Surgery (CRS)
Description: Cytoreductive surgery
Study NCT02124421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS)
Description: Cytoreductive surgery
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
Study NCT01359098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex Otic Suspension
Description: 4 gtt b.i.d. for 7 days.
Study NCT01359098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprodexa Otic Foam
Description: 0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
Study NCT04075981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Xeomin]
Description: Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
Study NCT04075981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug placebo
Description: All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
Study NCT00433654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: One hour MRI scan on the head and lower back.
Study NCT01424202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation Exsufflation
Description: After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse.
Study NCT04394182 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-Low-dose radiotherapy
Description: The total dose to be administered was 0.8 Gy in an only single session including both whole-lungs extended 1cm isometric in all directions.
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
Study NCT02124421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
Study NCT02124421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
Study NCT02124421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
Study NCT02124421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
Study NCT04394182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilatory support with oxygen therapy
Description: Oxygen Therapy: Nasal Cannula (NC); Ventimask (VMK) or VMK with reservoir
Study NCT00825448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hospitalization for a week
Description: Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 100/400 mg/12h; 7-10 days
Study NCT01487785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225+gemcitabine
Description: Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
Study NCT02605967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
Study NCT02605967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator choice of chemotherapy
Description: Commonly used chemotherapy as per investigator's choice. The dose and route of administration was the one described in each drug's label.
Study NCT03107299 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Communication methods to encourage adherence
Description: Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
Study NCT02088411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT02088411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym
Study NCT02088411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02145520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
Study NCT02145520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: use of placebo with standard therapy
Study NCT04118426 — intervention group
Intervention type: RADIATION
Intervention: Cognitive testing
Description: Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI).
Study NCT02812537 — intervention group
Intervention type: OTHER
Intervention: patients with conduct disorders
Description: interview with a specialist
Study NCT00804011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATC
Description: Automatic tube compensation
Study NCT00804011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PSV
Description: Pressure support ventilation
Study NCT01355835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation (ACTIVA PC, Medtronic)
Description: High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
Study NCT00079781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS® System implantation
Description: Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
Study NCT00079781 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: RNS® System implantation
Description: Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
Study NCT00079781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RNS® System implantation
Description: Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
Study NCT00079781 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RNS® System responsive stimulation
Description: The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
Study NCT00079781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RNS® System responsive stimulation
Description: The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
Study NCT00631241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
Study NCT04394182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg/12h
Study NCT01355835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation (ACTIVA PC, Medtronic)
Description: High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
Study NCT00631241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Lymphatic Mapping
Description: Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
Study NCT00705965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
Study NCT00705965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information session
Description: One information session about living with heart disease.
Study NCT00705965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual cardiological care
Description: Usual cardiological care
Study NCT00705965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual cardiological care
Description: Usual cardiological care
Study NCT03367351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Education
Description: Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
Study NCT03569423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study NCT03569423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study NCT01632215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentine
Description: Gabapentine 600 mg 01 dose
Study NCT01632215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill 01 dose
Study NCT02918058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MedSafer
Description: MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
Study NCT03997253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood and urine samples
Description: various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
Study NCT04509154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal pain therapy
Description: For the elaboration of the contents of the multi-component treatment of the mobile device application (APP), a set of guidelines has been developed for the care of one's own health, based on scientific evidence and adapted to the language of citizens, applying participatory methodology (Loewenson et al. 2014) and consensus, both by professionals (physicians,, nurses, psychologists, pharmacists, social educators and health professionals), and expert patients, who guarantee their validity, allowing the analysis and selection of the interventions that respond to the health problem. This intervention consists in the implementation of a protocol of standard activities of the interactive psychosocial therapy type.